MAP2K1 and cancer: Other mechanistic insight about copper action in cancer would be the oncogenic BRAFV600E that phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylates and activates ERK1 and ERK2 kinases, stimulating the MAPK (mitogen-activated protein kinase) pathway to promote cancer.